Vir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The S

Benzinga20:30

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Vir Biotechnology (VIR) and Alvotech (ALVO)

TipRanks15:50

TD Cowen Sticks to Their Buy Rating for Vir Biotechnology (VIR)

TipRanksMay 14 19:26

The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...

① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.

cls.cnMay 10 16:52

Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)

TipRanksMay 8 12:00

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow JonesMay 7 19:11